Can I Take Omega-3 (EPA/DHA) with Dayvigo (Lemborexant)?

What Is Lemborexant and How Does It Work?

Lemborexant is an orally administered dual orexin receptor antagonist approved by the FDA in December 2019 for adults with insomnia disorder [1]. It blocks orexin OX1R and OX2R receptors, suppressing the wake-promoting signal generated by the hypothalamic orexin (hypocretin) system. The approved doses are 5 mg and 10 mg taken within 30 minutes of bedtime [1].

Pharmacokinetic Profile

Lemborexant is absorbed rapidly, reaching peak plasma concentration (Tmax) at roughly one hour after dosing. It is highly protein-bound (greater than 94%) and metabolized primarily by CYP3A4, with minor contributions from CYP3A5 [2]. The terminal half-life is approximately 17 to 19 hours, which is why next-day sedation can persist at the 10 mg dose [2].

Because CYP3A4 handles the bulk of lemborexant clearance, any agent that strongly inhibits or induces this enzyme will substantially change lemborexant exposure. The FDA prescribing information explicitly contraindicates co-administration with strong CYP3A4 inhibitors such as itraconazole or clarithromycin, and warns against combined use with moderate inhibitors like fluconazole [1].

Protein Binding and Displacement

High protein binding (greater than 94%) means that a second highly protein-bound compound could theoretically displace lemborexant and transiently raise free drug concentrations. This displacement mechanism is rarely clinically significant in practice unless both drugs have very high binding and narrow therapeutic indices [3].

What Are Omega-3 Fatty Acids (EPA and DHA)?

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long-chain polyunsaturated fatty acids found in fatty fish and algal sources. At dietary doses (250 to 500 mg/day combined), they support cardiovascular health. At prescription doses (4 g/day of icosapentaenoic acid as Vascepa, or 4 g/day of EPA+DHA as Lovaza), they reduce fasting serum triglycerides by 20 to 30% [4].

Antiplatelet Mechanism

EPA and DHA compete with arachidonic acid for cyclooxygenase (COX) binding, reducing thromboxane A2 synthesis and blunting platelet aggregation [5]. This effect becomes clinically measurable above approximately 2 to 3 g of combined EPA+DHA per day, as documented in a dose-ranging platelet function study published in Prostaglandins, Leukotrienes and Essential Fatty Acids [5]. Below 1 g/day, antiplatelet effects are generally considered subclinical in otherwise healthy adults.

Triglyceride-Lowering Effect

The REDUCE-IT trial (N=8,179) tested icosapentaenoic acid ethyl ester (Vascepa) 4 g/day in statin-treated patients with elevated triglycerides and established cardiovascular disease or diabetes. At a median follow-up of 4.9 years, the treatment group showed a 25% relative risk reduction in major adverse cardiovascular events versus placebo [6]. The triglyceride-lowering effect itself was approximately 19% from baseline at 1 year [6]. This is relevant context for patients also managing metabolic conditions alongside insomnia.

Does Omega-3 Interact Pharmacokinetically with Lemborexant?

No clinically significant pharmacokinetic interaction between omega-3 fatty acids and lemborexant has been identified in the published literature or in the FDA-approved labeling for Dayvigo [1].

CYP3A4 Enzyme Assessment

Omega-3 fatty acids are not CYP3A4 inhibitors or inducers at doses used in supplementation or even at prescription doses. A systematic review of omega-3 and drug metabolism published in the British Journal of Clinical Pharmacology found no clinically relevant inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 by EPA or DHA at doses up to 4 g/day [7]. Because CYP3A4 is the primary clearance pathway for lemborexant, this finding means omega-3 supplementation is not expected to raise or lower lemborexant blood levels.

P-Glycoprotein and Transporter Effects

Lemborexant is also a P-glycoprotein (P-gp) substrate. Omega-3 fatty acids have not been shown to inhibit P-gp at physiological concentrations, further reducing the likelihood of a transporter-mediated interaction [7].

Protein Binding Displacement

Both omega-3 fatty acids (particularly DHA) and lemborexant bind plasma proteins, but at separate binding sites. In vitro studies on plasma protein displacement by fatty acids have not demonstrated displacement of tightly bound drugs at physiologic fatty acid concentrations [3]. Clinically observable displacement would require fatty acid concentrations well above those achieved with standard supplementation.

What Is the Pharmacodynamic Concern?

The relevant concern is pharmacodynamic rather than pharmacokinetic. Lemborexant itself has no direct antiplatelet or anticoagulant mechanism. The issue arises when a patient is simultaneously taking omega-3 at high doses alongside an anticoagulant (warfarin, apixaban, rivaroxaban) or antiplatelet drug (aspirin, clopidogrel), since the combined antiplatelet burden could increase bleeding risk [8].

Omega-3 and Antiplatelet Potentiation

A randomized crossover study (N=30) published in Thrombosis Research measured platelet aggregation in patients taking aspirin 100 mg/day with and without added EPA+DHA 3 g/day. Adding EPA+DHA produced a statistically significant further reduction in ADP-induced platelet aggregation (P<0.01) compared with aspirin alone [8]. Lemborexant does not independently alter platelet function, but a patient on both aspirin and high-dose omega-3 who then adds Dayvigo is managing a three-drug regimen and should ensure their prescriber has a full medication list.

Sedation Additivity

EPA and DHA do not act on orexin receptors, GABA-A receptors, or other sedation pathways and are not expected to potentiate the CNS-depressant or soporific effects of lemborexant. This distinguishes omega-3 from supplements like valerian, melatonin, or kava, where additive sedation is a legitimate concern [9].

Triglyceride Monitoring Context

Patients with hypertriglyceridemia may be prescribed both a GLP-1 receptor agonist or statin and prescription omega-3. If that same patient develops insomnia and is prescribed lemborexant, the clinician's metabolic monitoring plan should be documented separately. Lemborexant does not affect lipid panels [2], so any triglyceride change observed after adding omega-3 reflects the omega-3 effect alone.

Dose Thresholds That Change the Risk Calculus

Not all omega-3 use is equivalent. The dose determines whether the antiplatelet signal is clinically meaningful.

Low-Dose Supplementation (250 to 1,000 mg EPA+DHA/day)

This covers most over-the-counter fish oil capsules (typically 300 to 600 mg EPA+DHA per 1 g softgel) and the AHA's recommended intake of 1 g/day for patients with coronary artery disease [10]. At this dose range, antiplatelet activity is subclinical. A patient taking a standard one-softgel daily fish oil alongside lemborexant 5 mg or 10 mg does not require any special monitoring beyond what is standard for lemborexant alone.

Moderate-Dose Supplementation (1 to 2 g EPA+DHA/day)

Antiplatelet effects are detectable on laboratory assay but rarely translate to clinical bleeding events in patients not already on anticoagulants [5]. Prescriber disclosure is reasonable but not urgent for otherwise healthy patients.

High-Dose or Prescription Omega-3 (2 to 4 g EPA+DHA/day)

At 4 g/day of prescription formulations (Vascepa or Lovaza), platelet function changes are measurable and clinically relevant in patients on antithrombotic regimens [8]. If a patient takes Dayvigo plus warfarin or a direct oral anticoagulant plus high-dose omega-3, the prescriber should be informed so an INR check or bleeding-symptom review can be scheduled.

Practical Guidance for Patients Already Taking Both

Patients who are already taking omega-3 and lemborexant together and have not reported problems are likely fine, particularly at standard supplement doses. The following steps help maintain safety.

Disclose the Full Supplement List

Tell your prescriber or pharmacist the exact daily dose of EPA+DHA you are taking, not just the total fish oil softgel weight. A "1,000 mg fish oil" softgel may contain 300 mg of EPA+DHA or as much as 800 mg depending on the product. The American Heart Association recommends patients read the Supplement Facts panel for EPA and DHA specifically, not total fish oil weight [10].

Watch for Bleeding Symptoms

Signs worth reporting include unusual bruising, prolonged bleeding from cuts, or blood in urine or stool. These would not be expected from omega-3 or lemborexant alone at standard doses, but they become relevant if omega-3 is stacked with other antithrombotic drugs [8].

Timing and Dose Separation

No evidence supports separating omega-3 and lemborexant doses by a fixed window. Because there is no pharmacokinetic interaction, staggered timing offers no mechanistic benefit [7]. Omega-3 softgels are typically taken with food (morning or evening meal) to reduce GI upset and improve absorption [4]; lemborexant is taken at bedtime [1]. That natural timing separation occurs without any special effort.

Pregnancy and Breastfeeding

Lemborexant is listed as Pregnancy Category C (animal data showed developmental harm; no adequate human trials) [1]. DHA supplementation during pregnancy is widely recommended for fetal neurodevelopment at 200 to 300 mg/day [11]. Any patient who is pregnant or planning pregnancy should discuss both agents with their OB-GYN or maternal-fetal medicine specialist before continuing or starting either.

What Monitoring Is Appropriate?

For most patients on standard-dose omega-3 with lemborexant, no additional monitoring beyond the standard Dayvigo follow-up is needed. The FDA prescribing information for lemborexant calls for assessment of daytime sedation, sleep behavior abnormalities, and mood changes at each visit [1].

When to Add Lab Monitoring

Add lipid panel monitoring (fasting triglycerides, total cholesterol, LDL, HDL) if the patient is taking prescription-dose omega-3 (2 to 4 g/day) or if metabolic disease (hypertriglyceridemia, type 2 diabetes, or metabolic syndrome) is present [4]. Lemborexant does not alter lipid metabolism and will not confound this result.

INR for Warfarin Users

Patients on warfarin who add high-dose omega-3 (>2 g/day EPA+DHA) should have their INR rechecked 1 to 2 weeks after starting omega-3. A prospective cohort study published in Thrombosis and Haemostasis (N=150 warfarin patients) found that adding omega-3 above 3 g/day produced a clinically meaningful INR increase in 18% of participants [12]. Lemborexant does not affect INR, but the presence of a sleep disorder requiring pharmacotherapy is relevant context for the treating internist managing anticoagulation.

Evidence Gaps and Current Limitations

No published randomized controlled trial has directly tested the combination of lemborexant and omega-3 fatty acids as a primary endpoint. The interaction assessment above is therefore built from:

1. Lemborexant's known PK profile (CYP3A4 metabolism, protein binding) [2]
2. Omega-3's known pharmacology (no CYP3A4 effect, antiplatelet at high dose) [5][7]
3. General principles of pharmacodynamic interaction assessment outlined in the FDA's guidance on drug interaction studies [13]

The absence of a direct interaction trial means clinicians should continue to use clinical judgment. Any novel symptom appearing after adding omega-3 to a lemborexant regimen, particularly unusual somnolence or bleeding signs, warrants a medication review.

Summary of the Clinical Picture

Omega-3 fatty acids do not alter lemborexant blood levels through CYP3A4 or transporter mechanisms. At dietary to moderate supplement doses (up to 2 g EPA+DHA/day), the combination with Dayvigo carries no clinically meaningful interaction concern beyond standard prescribing precautions for lemborexant itself. At prescription doses (3 to 4 g/day), the antiplatelet effect of omega-3 deserves attention in patients already on antithrombotic therapy. Patients without antithrombotic co-medications and without bleeding risk factors may continue standard-dose omega-3 with lemborexant. Disclose all supplements to your prescriber and pharmacist, and report any unexpected bruising or bleeding promptly.

The FDA Dayvigo prescribing information states: "The recommended dose of DAYVIGO is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. If the 5 mg dose is well-tolerated but not efficacious, the dose can be increased to 10 mg" [1].

The American Heart Association's 2019 science advisory on omega-3 and cardiovascular risk notes: "Prescription omega-3 fatty acid medications are the only omega-3 formulations with proven, consistent triglyceride-lowering efficacy and FDA-approved labeling for hypertriglyceridemia" [10].